Trial Profile
Safety of ibrutinib in terms of hemostasis alteration and hemorrhagic adverse effects in patients with mantle cell lymphoma, chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jan 2017
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 05 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology